| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Trans-sialidase of Trypanosoma cruzi has been shown as an important key factor of T. cruzi in Chagas’ disease. In this research, we have obtained some trans-sialidase inhibitor molecules from the first random screening of 9,600 core chemical compound library of open innovation center for drug discovery, The University of Tokyo, and further analysis of the derivatives based on the positive compounds at the first screening. No effective inhibitors enough for functional analysis have been reported yet and we are currently engaged in experiments with the new trans-sialidase inhibitors how trans-sialidase influences the parasite process of infection to and development in the host cells. We believe the inhibitor is a key for a new therapeutic agent of Chagas’ disease.
|
